Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
436.98 DKK | -1.42% |
|
-2.00% | -29.36% |
07:33am | Kailera touts late-stage win for weight-loss drug in China | RE |
05:22am | Indutrade: Life Science Achieved Positive Organic Growth Excluding Novo Nordisk Sales | FW |
Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 127B | 141B | 177B | 232B | 290B | |||||
Total Revenues | 127B | 141B | 177B | 232B | 290B | |||||
Cost of Goods Sold, Total | 20.93B | 23.66B | 28.45B | 35.76B | 43.56B | |||||
Gross Profit | 106B | 117B | 149B | 196B | 247B | |||||
Selling General & Admin Expenses, Total | 36.89B | 41.06B | 50.68B | 61.6B | 67.37B | |||||
R&D Expenses | 15.11B | 17.2B | 23.29B | 31.03B | 40.07B | |||||
Other Operating Expenses | -460M | -456M | -1.08B | -119M | -476M | |||||
Other Operating Expenses, Total | 51.54B | 57.8B | 72.89B | 92.51B | 107B | |||||
Operating Income | 54.48B | 59.34B | 75.62B | 104B | 140B | |||||
Interest Expense, Total | -390M | -289M | -378M | -542M | -1.64B | |||||
Interest And Investment Income | 337M | 231M | 239M | 1.07B | 1.84B | |||||
Net Interest Expenses | -53M | -58M | -139M | 527M | 198M | |||||
Income (Loss) On Equity Invest. | 149M | -24M | -189M | 81M | -17M | |||||
Currency Exchange Gains (Loss) | -747M | 344M | -4.65B | 1.65B | -1.02B | |||||
Other Non Operating Income (Expenses) | -150M | -122M | -181M | -197M | -289M | |||||
EBT, Excl. Unusual Items | 53.68B | 59.48B | 70.46B | 106B | 139B | |||||
Merger & Related Restructuring Charges | - | -124M | -51M | - | -978M | |||||
Gain (Loss) On Sale Of Investments | -195M | 296M | -587M | 37M | -17M | |||||
Gain (Loss) On Sale Of Assets | - | - | - | - | - | |||||
Asset Writedown | -350M | -573M | -760M | -1.41B | -10.56B | |||||
Other Unusual Items | - | - | - | - | - | |||||
EBT, Incl. Unusual Items | 53.13B | 59.08B | 69.06B | 105B | 127B | |||||
Income Tax Expense | 10.99B | 11.32B | 13.54B | 20.99B | 26.2B | |||||
Earnings From Continuing Operations | 42.14B | 47.76B | 55.52B | 83.68B | 101B | |||||
Net Income to Company | 42.14B | 47.76B | 55.52B | 83.68B | 101B | |||||
Net Income - (IS) | 42.14B | 47.76B | 55.52B | 83.68B | 101B | |||||
Net Income to Common Incl Extra Items | 42.14B | 47.76B | 55.52B | 83.68B | 101B | |||||
Net Income to Common Excl. Extra Items | 42.14B | 47.76B | 55.52B | 83.68B | 101B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 9.03 | 10.4 | 12.26 | 18.67 | 22.67 | |||||
Basic EPS - Continuing Operations | 9.03 | 10.4 | 12.26 | 18.67 | 22.67 | |||||
Basic Weighted Average Shares Outstanding | 4.67B | 4.59B | 4.53B | 4.48B | 4.45B | |||||
Net EPS - Diluted | 9 | 10.37 | 12.22 | 18.62 | 22.63 | |||||
Diluted EPS - Continuing Operations | 9 | 10.37 | 12.22 | 18.62 | 22.63 | |||||
Diluted Weighted Average Shares Outstanding | 4.68B | 4.61B | 4.54B | 4.49B | 4.46B | |||||
Normalized Basic EPS | 7.19 | 8.09 | 9.72 | 14.79 | 19.47 | |||||
Normalized Diluted EPS | 7.17 | 8.07 | 9.69 | 14.75 | 19.43 | |||||
Dividend Per Share | 4.55 | 5.2 | 6.2 | 9.4 | 11.4 | |||||
Payout Ratio | 47.75 | 45.06 | 45.57 | 37.96 | 43.71 | |||||
American Depositary Receipts Ratio (ADR) | 0 | 0 | 0 | 0 | 0 | |||||
Supplemental Items | ||||||||||
EBITDA | 58.79B | 63.55B | 80.93B | 110B | 147B | |||||
EBITA | 55.57B | 60.21B | 77.02B | 106B | 142B | |||||
EBIT | 54.48B | 59.34B | 75.62B | 104B | 140B | |||||
EBITDAR | 59.1B | 64.86B | 82.42B | 112B | - | |||||
Effective Tax Rate - (Ratio) | 20.69 | 19.17 | 19.6 | 20.05 | 20.6 | |||||
Total Current Taxes | 10.99B | 13.27B | 18.17B | 25B | 32.25B | |||||
Total Deferred Taxes | -2M | -1.94B | -4.63B | -4.01B | -6.05B | |||||
Normalized Net Income | 33.55B | 37.18B | 44.04B | 66.28B | 86.72B | |||||
Interest on Long-Term Debt | 97M | - | - | - | - | |||||
Non-Cash Pension Expense | 138M | 139M | 185M | 126M | 156M | |||||
Supplemental Operating Expense Items | ||||||||||
Selling and Marketing Expenses | 32.93B | 37.01B | 46.22B | 56.74B | 62.09B | |||||
General and Administrative Expenses | 3.96B | 4.05B | 4.47B | 4.86B | 5.28B | |||||
Research And Development Expense From Footnotes | 15.46B | 17.77B | 24.05B | 32.44B | 48.06B | |||||
Net Rental Expense, Total | 312M | 1.3B | 1.49B | 1.83B | - | |||||
Imputed Operating Lease Interest Expense | 131M | 163M | 172M | 301M | - | |||||
Imputed Operating Lease Depreciation | 181M | 1.14B | 1.32B | 1.53B | - | |||||
Stock-Based Comp., Other (Total) | 823M | 1.04B | 1.54B | 2.15B | 2.29B | |||||
Total Stock-Based Compensation | 823M | 1.04B | 1.54B | 2.15B | 2.29B |
- Stock Market
- Equities
- NOVO B Stock
- Financials Novo Nordisk A/S
- Income Statement
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition